These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 6352651)

  • 21. [Monotherapy of systematic Pseudomonas aeruginosa infections with ceftazidime. The causes of therapeutic failures].
    Blaser J; Bauernfeind A; Vogt M; Lüthy R
    Dtsch Med Wochenschr; 1983 Sep; 108(35):1312-7. PubMed ID: 6411442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients.
    Wang FD; Liu CY; Hsu HC; Gau JP; Chau WK; Haung ML; Ho CH
    Chemotherapy; 1999; 45(5):370-9. PubMed ID: 10473925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical experience with ceftazidime in urology in Japan.
    Kawamura N
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():65-70. PubMed ID: 6352657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ceftazidime in the therapy of serious Gram-negative bacillary infections.
    Pottage JC; Karakusis PH; Fliegelman RM; Levin S; Trenholme GM
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():223-8. PubMed ID: 6352623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cephacetrile: clinical evaluation in 27 patients.
    Hodges GR; Scholand JF; Perkins RL
    Antimicrob Agents Chemother; 1973 Feb; 3(2):228-34. PubMed ID: 4790588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ceftazidime in the treatment of pediatric patients with severe urinary tract infections due to Pseudomonas spp.
    Rusconi F; Assael BM; Florioli A; Zaffaroni G
    Antimicrob Agents Chemother; 1984 Mar; 25(3):395-7. PubMed ID: 6372686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ceftazidime in patients with Pseudomonas infections.
    Eron LJ; Park CH; Hixon DL; Goldenberg RI; Poretz DM
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():161-9. PubMed ID: 6225762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of cefepime versus ceftazidime in the treatment of severe infections.
    Huang CK; Chen YS; Lee SS; Lin WR; Tsai HC; Lin HH; Wann SR; Chen JY; Yen MY; Liu YC
    J Microbiol Immunol Infect; 2002 Sep; 35(3):159-67. PubMed ID: 12380788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of ceftazidime in the treatment of severe localized and systemic infections.
    Gabrielli GB; Corrocher R; De Sandre G
    Int J Clin Pharmacol Ther Toxicol; 1984 Mar; 22(3):167-9. PubMed ID: 6370875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ceftazidime therapy of serious bacterial infections.
    Eron LJ; Goldenberg RI; Park CH; Poretz DM
    Antimicrob Agents Chemother; 1983 Feb; 23(2):236-41. PubMed ID: 6340601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. L-658,310, a new injectable cephalosporin. III. Experimental chemotherapeutics and pharmacokinetics in laboratory animals.
    Gilfillan EC; Pelak BA; Weissberger BA; Abruzzo GK; Fromtling RA; Bland JA; Hadley SK; Gadebusch HH
    J Antibiot (Tokyo); 1989 May; 42(5):815-22. PubMed ID: 2656617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ceftazidime in the treatment of complicated respiratory and urinary tract infections.
    Loebis LH; Williams KJ
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():59-64. PubMed ID: 6352656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of ceftazidime and tobramycin in the treatment of complicated urinary tract infections.
    Cox CE
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():47-52. PubMed ID: 6352654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aspects of clinical trials with ceftazidime worldwide.
    Foord RD
    Am J Med; 1985 Aug; 79(2A):110-3. PubMed ID: 3895913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients.
    Fainstein V; Bodey GP; Elting L; Bolivar R; Keating MJ; McCredie KB; Valdivieso M
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():101-10. PubMed ID: 6352612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carbenicillin plus cephalothin or cefazolin as therapy for infections in neutropenic patients.
    Bodey GP; Valdivieso M; Feld R; Rodriguez V; McCredie K
    Am J Med Sci; 1977; 273(3):309-18. PubMed ID: 326048
    [No Abstract]   [Full Text] [Related]  

  • 37. Ceftazidime: a new approach in the treatment of moderate and severe infections.
    Abbas AM; Taylor MC; Newby D; Jones RB; Rigby CC; Haste AR; Cantor AM
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():147-52. PubMed ID: 6352615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ceftazidime compared to tobramycin and ticarcillin in immunocompromised haematological patients.
    Reilly JT; Brada M; Bellingham AJ; Hart CA; Bennet C
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():89-92. PubMed ID: 6352660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Combination of a 3d-generation cephalosporin (cefotaxime or ceftazidime) and a new quinolone (pefloxacine) in the treatment of febrile episodes in neutropenic diseases (37 cases)].
    Guy H; Caillot D; Solary E; Bielefeld P; Portier H; Kazmierczak A
    Presse Med; 1987 Dec; 16(43):2172-5. PubMed ID: 2963306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ceftazidime, as a single antibiotic, in the treatment of multi-resistant Gram-negative infections in intensive care.
    Gasparetto A; Delogu G
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():171-5. PubMed ID: 6352617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.